Auto-populated list of related Clinical Trials
(Breast, Cleft Lip and Palate, Hand, Lymphedema, Oral, Skin, Trauma)

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

This study will collect rates of local/regional recurrence in select patients who do not receive radiation treatment after lumpectomy surgery. These women must be postmenopausal; have hormone receptor-positive, Her2-negative tumors; have Oncotype-DX RS less than or equal to 18; and plan to receive endocrine therapy. In this way, this study seeks to collect prospective data supporting the idea that this is a population at sufficiently low risk of local/regional recurrence that omission of adjuvant radiation might be a reasonable option.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan Cancer Center

Collaborator: Loyola University

Intervention(s):

  • Other: endocrine therapy alone without radiotherapy

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Postmenopausal status, as defined by (a) patients age 60 or greater, or, (b) patients
   age 50-69 with either (a) s/p bilateral oophorectomy, or, (b) intact uterus without
   menses in the past 12 months, or, (c) biochemical confirmation of postmenopausal
   status.

   - Histopathological confirmation of Stage 1 (pT1N0M0) invasive breast cancer status post
   breast conserving surgery

   - Negative axillary nodes (isolated tumor cells with no cluster measuring >0.2mm
   allowed)

      - Allowable options for axillary staging include:

      - Sentinel node biopsy only

      - Sentinel node biopsy followed by axillary dissection

      - Axillary dissection only

   - Margins of excision ≥2mm

   - ER+, PR+, Her2 - using the current College of American Pathologists guidelines

   - Oncotype-DX RS ≤ 18

   - Disease must be unifocal on clinical, radiologic, and pathologic examination

   - Registration within 90 days of last surgical procedure for breast cancer treatment

   - Patient must willingly sign study specific informed consent prior to study entry

   - Patient must be a candidate for and willing to take endocrine therapy for minimum of 5
   years (aromatase inhibitor or tamoxifen). Patients who have already begun endocrine
   therapy after lumpectomy are eligible.

   - Patient must have had breast imaging (mammogram or MRI) of the ipsilateral breast
   within 6 months and contralateral breast within 1 year of study entry.

   - Patient must have Zubrod performance status 0-2

Exclusion Criteria:

   - Evidence of multifocal or multicentric breast cancer that has not been biopsy-proven
   negative. Note that MRI is not required for this study, but if performed, evidence of
   disease beyond the site of the primary tumor in the ipsilateral breast or in the
   contralateral breast must be biopsy-proven not to be malignant before registration.

   - Metastatic disease. Note that no specific staging studies are mandated, but any
   studies performed must not provide clear evidence of metastatic spread.

   - Previous radiation therapy to the breast region

   - Prior DCIS or invasive breast cancer

   - Bilateral breast cancer

   - Prior non-breast invasive malignancy other than non-melanoma skin cancer, unless there
   has been no evidence of disease for at least 5 years

   - Known carrier of a mutation known to predispose towards breast cancer development
   (including BRCA-1 and BRCA-2). Note: testing for mutation status is not required for
   this protocol; this criterion applies only to patients who have been tested and have
   known carrier status.

Ages Eligible for Study

50 Years - 69 Years

Genders Eligible for Study

Female

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amanda Simmons
650-724-4606
Recruiting